LINKÖPING, Sweden--(BUSINESS WIRE)--AMRA Medical, in collaboration with researchers from National Center of Neurology and Psychiatry in Tokyo as well as Japanese pharmaceutical company Daiichi-Sankyo, are excited to announce the publication of a recent study investigating the utility of AMRA’s fat-referenced MRI measurements in inflammatory myopathies - specifically, sporadic inclusion body myositis (sIBM)..

瑞典林克平——（商业新闻短讯）——AMRA Medical与东京国家神经病学和精神病学中心以及日本制药公司Daiichi Sankyo的研究人员合作，很高兴宣布最近发表的一项研究，该研究调查了AMRA脂肪参考MRI测量在炎症性肌病（特别是散发性包涵体肌炎（sIBM））中的效用。。

The study, which is published in Muscle & Nerve, demonstrated that the fat-referenced MRI-methodology powering the measurements can be used for volumetric muscle composition analysis in subjects with sIBM, and established a clear relationship between muscle atrophy, muscle fat content, and functional decline over a 12-month period.

这项发表在《肌肉与神经》上的研究表明，为测量提供动力的脂肪参考MRI方法可用于sIBM受试者的体积肌肉成分分析，并在12个月的时间内建立了肌肉萎缩，肌肉脂肪含量和功能下降之间的明确关系。

Importantly, these findings validated the performance of AMRA’s MRI-based muscle and fat biomarkers in sIBM, building upon on recent work that confirmed the utility of these biomarkers in other neuromuscular diseases, namely Facioscapulohumeral Muscular Dystrophy (FSHD)..

重要的是，这些发现验证了AMRA基于MRI的肌肉和脂肪生物标志物在sIBM中的表现，其基础是最近的研究证实了这些生物标志物在其他神经肌肉疾病（即面肩肱型肌营养不良症（FSHD））中的实用性。。

Using standardized processes for scanner certification and image acquisition, scans from 10 sIBM patients were analyzed using the cloud-based service, AMRAⓇ Researcher. AMRA’s unique muscle quantification biomarkers – including muscle fat fraction, lean muscle volume, and muscle fat infiltration – were collected for each participant to characterize muscle composition within the disease pathology.

使用标准化的扫描仪认证和图像采集流程，使用基于云的服务AMRA研究人员对10名sIBM患者的扫描进行了分析。为每位参与者收集了AMRA独特的肌肉定量生物标志物，包括肌肉脂肪分数，瘦肌肉体积和肌肉脂肪浸润，以表征疾病病理学中的肌肉组成。

The results of the study support the use of these muscle biomarkers as reliable composite endpoints in sIBM drug trials..

该研究的结果支持在sIBM药物试验中使用这些肌肉生物标志物作为可靠的复合终点。。

The study comes at a time in neuromuscular disease research where more actionable, unique endpoints are required to assess disease progression and response to treatments, and push drug development for these diseases forward. AMRA’s success in demonstrating the utility of these fat-referenced MRI-based muscle composition biomarkers in FSHD and now in inflammatory myopathies such as sIBM is a testament to the rigor and reproducibility of these composite measurements, transcending various pathologies and allowing for the wide applicability of this biomarker suite to neuromuscular disease research in general..

这项研究正值神经肌肉疾病研究之际，需要更可行，独特的终点来评估疾病进展和对治疗的反应，并推动这些疾病的药物开发。AMRA成功证明了这些脂肪参考的基于MRI的肌肉成分生物标志物在FSHD中的实用性，以及现在在炎症性肌病（如sIBM）中的应用，证明了这些复合测量的严格性和可重复性，超越了各种病理学，并允许这种生物标志物套件广泛适用于一般的神经肌肉疾病研究。。

AMRA is committed to helping pioneer the next wave of neuromuscular disease trials using MRI-based analyses, by delivering biomarkers that enable standardized evaluation of disease progression and treatment response in conditions with high unmet needs. With AMRA, researchers can augment clinical trials with powerful endpoints to gain more holistic insights and, ultimately, advance their clinical pipeline..

AMRA致力于通过提供生物标志物，在未满足需求的情况下，对疾病进展和治疗反应进行标准化评估，从而帮助开创下一波基于MRI的神经肌肉疾病试验。通过AMRA，研究人员可以通过强大的终点来扩大临床试验，以获得更全面的见解，并最终推进其临床流程。。

Learn how AMRA can help you advance neuromuscular disease research and drug development by visiting our website, or get in touch with our knowledgeable scientists at info@amramedical.com. You can read the full publication in Muscle & Nerve here.

通过访问我们的网站，或与我们知识渊博的科学家联系，了解AMRA如何帮助您推进神经肌肉疾病的研究和药物开发info@amramedical.com.你可以在这里阅读肌肉与神经的完整出版物。

About AMRA Medical

关于AMRA Medical

AMRA Medical is a health informatics and precision medicine company that is pioneering body composition analysis, providing cutting-edge solutions to advance both clinical research and patient care initiatives. AMRA's gold-standard technology delivers multiple fat and muscle biomarkers - derived simply from rapid whole-body MRI scans.

AMRA Medical是一家健康信息学和精准医学公司，开创了人体成分分析的先河，为推进临床研究和患者护理计划提供了前沿解决方案。。

AMRA is committed to driving transformative care and simplifying vital decision-making in both research and clinical care settings by offering support services via their innovative platform..

AMRA致力于通过其创新平台提供支持服务，推动变革性护理，简化研究和临床护理环境中的重要决策。。

Learn more about AMRA Medical’s MRI-based solutions at https://amramedical.com/solutions, or connect with our team of experts for a detailed discussion at info@amramedical.com.

了解有关AMRA Medical基于MRI的解决方案的更多信息，请访问https://amramedical.com/solutions，或与我们的专家团队联系，在info@amramedical.com.

Follow AMRA on LinkedIn for the latest updates in fat distribution and muscle composition assessments in disease research.

关注LinkedIn上的AMRA，了解疾病研究中脂肪分布和肌肉成分评估的最新更新。